Emerging Drugs
Emerging Drugs

Emerging Drugs

The ALS Association is committed to urgently finding new treatments and a cure for ALS. That means supporting a robust drug development pipeline and maximizing participation in clinical trials.

We highly encourage people with ALS to participate in trials whenever possible, because enrollment is key to making new therapies available for our community as quickly as possible. Enrollment in clinical trials is voluntary, and people must consent prior to participation and have the right to understand all pertinent details of the trial.

For a drug to be approved by the U.S. Food and Drug Administration (FDA), drugs go through the interventional clinical trial process or pipeline.

Learn more about several potential new ALS drugs that are in different stages of the pipeline and their current status.

Emerging ALS Drugs

AMX0035 (Amylyx Pharmaceuticals)
Edaravone (Mitsubishi Tanabe Pharma Corporation)
Tofersen (Biogen/Ionis Pharmaceuticals)

Related Topics

  • Learn more about clinical trials here.
  • Search for a trial in your area here.
Print Friendly and PDF
Emerging Drugs